C2E2
Treatment of internal radioactive contamination (e.g., from nuclear accidents, radiological incidents)
Key Facts
About Captura Biopharma
Captura Biopharma is addressing a significant unmet medical need in radiation emergency preparedness with its lead oral therapeutic candidate, C2E2. The company leverages a team with deep pharmaceutical development, regulatory, and emergency medicine expertise to advance a product intended for rapid, mass administration following a nuclear incident. Operating as a private, pre-revenue entity, Captura is in the early development stage, targeting a niche but strategically important market driven by government and institutional preparedness programs. Its success hinges on navigating complex regulatory pathways and demonstrating efficacy in a field with limited treatment options.
View full company profile